# Us2.ai

> Us2.ai is a Singapore-based medtech company that builds FDA-cleared, CE-marked AI software to automate echocardiography (cardiac ultrasound) analysis and reporting. Its vendor-neutral platform - branded the AI Echo Copilot - turns raw DICOM echo studies into fully editable, structured clinical reports in seconds, detecting conditions such as heart failure, aortic stenosis, pulmonary hypertension and cardiac amyloidosis. Founded in 2017 as eko.ai and rebranded to Us2.ai in 2021, the company aims to widen access to expert-level cardiac diagnostics across hospitals, echo labs and clinical-trial core labs worldwide.

- **Founded:** 2017
- **Headquarters:** Singapore, Singapore
- **Founders:** James Hare (Co-founder & CEO), Dr. Carolyn Lam (Co-founder & Head of Medical Affairs (cardiologist)), Dr. Yoran Hummel (Co-founder & President)
- **Team size:** ~32 employees (aggregators list 11-50)
- **Products:** Us2.v1, Us2.v2, AI Echo Copilot, Cardiac amyloidosis detection, HCM (hypertrophic cardiomyopathy) AI model
- **Notable:** FDA 510(k) clearance for Us2.v1 (September 2021) - claimed first software to fully automate a complete echo report, US$15M Series A led by IHH Healthcare and HEAL Partners (April 2022), Research published in Nature Communications (November 2023)

## Products & services

- **Us2.v1** — First fully automated echocardiography decision-support software; analyzes 2D and Doppler images to produce a complete, editable echo report. FDA 510(k) cleared (K210791).
- **Us2.v2** — Next-generation platform measuring ~45 automated echo parameters and adding strain (GLS) imaging; FDA 510(k) cleared.
- **AI Echo Copilot** — Brand for the vendor-neutral platform delivering zero-click, real-time echo reports and disease detection (heart failure, aortic stenosis, pulmonary hypertension, stress echo).
- **Cardiac amyloidosis detection** — Deep-learning model that flags cardiac amyloidosis from a standard echo view; FDA cleared and CE marked.
- **HCM (hypertrophic cardiomyopathy) AI model** — AI model for detecting hypertrophic cardiomyopathy from echo imaging.

## Achievements

- FDA 510(k) clearance for Us2.v1 (September 2021) - claimed first software to fully automate a complete echo report
- US$15M Series A led by IHH Healthcare and HEAL Partners (April 2022)
- Research published in Nature Communications (November 2023)
- Us2.v2 FDA clearance (April 2024) with ~45 automated parameters and strain
- CE Mark Class IIb for latest version (June 2025); available in 28+ markets
- FDA clearance and CE mark for cardiac amyloidosis detection (2025)
- AI-ECHO randomized trial presented as Late-Breaking Science at AHA 2024; AI-SCREEN-CA late-breaker at AHA 2025
- SOC 2 Type II, ISO 27001:2022 and BSI certifications

## Latest updates

- **2024-04** — Us2.v2 receives FDA 510(k) clearance, adding strain imaging and ~45 automated echo parameters.
- **2024-12** — AI-ECHO randomized trial presented as Late-Breaking Science at AHA 2024.
- **2025-06** — Latest platform version certified under CE Mark Class IIb.
- **2025-09** — New hypertrophic cardiomyopathy (HCM) AI model introduced.
- **2025-11** — AI-SCREEN-CA cardiac amyloidosis screening study presented as late-breaker at AHA 2025.
- **2026-07** — Canon Medical Systems USA reseller partnership announced; Endeavor Health + Siemens integration reported to cut analysis time by 10-12 minutes per study.

## Links

- Website: https://us2.ai
- LinkedIn: https://www.linkedin.com/company/us2-ai
- Twitter/X: https://x.com/us2_ai
- YouTube: https://www.youtube.com/@US2ai
- Facebook: https://facebook.com/Us2ai

---

Profile page: https://yespress.io/us2-ai
Published by YesPress — https://yespress.io
Last updated: 2026-07-24